SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Litzow M)
 

Search: WFRF:(Litzow M) > Does FLT3 Mutation ...

  • Deol, AbhinavWayne State Univ, Karmanos Canc Inst, Dept Oncol, 4100 John R,4 HWCRC, Detroit, MI 48201 USA. (author)

Does FLT3 Mutation Impact Survival After Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia? : A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-06-17
  • Wiley,2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-310019
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-310019URI
  • https://doi.org/10.1002/cncr.30140DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:134531556URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild-type (WT) group (38% [95% confidence interval (CI), 30%-45%] vs 28% [95% CI, 24%-33%]; P = .04; relative risk, 1.60 [95% CI, 1.15-2.22]; P = .0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia-free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3-year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%-57%; WT group: 55%, 95% CI, 50%-60%; P = .20). CONCLUSIONS: The current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long-term survivors.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sengsayadeth, SalykaVanderbilt Univ, Med Ctr, Nashville, TN USA. (author)
  • Ahn, Kwang WooMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (author)
  • Wang, Hai-LinMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Aljurf, MahmoudKing Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia. (author)
  • Antin, Joseph HarryDana Farber Canc Inst, Dept Med Oncol, Ctr Hematol Oncol, Boston, MA 02115 USA. (author)
  • Battiwalla, MinooNHLBI, Hematol Branch, Bethesda, MD 20892 USA. (author)
  • Bornhauser, MartinCarl Gustav Carus Univ Hosp, Dresden, Germany. (author)
  • Cahn, Jean-YvesUniv Hosp, Dept Hematol, Grenoble, France. (author)
  • Camitta, BruceMed Coll Wisconsin, Midwest Ctr Canc & Blood Disorders, Milwaukee, WI 53226 USA.;Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. (author)
  • Chen, Yi-BinMassachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. (author)
  • Cutler, Corey S.Dana Farber Canc Inst, Dept Med Oncol, Ctr Hematol Oncol, Boston, MA 02115 USA. (author)
  • Gale, Robert PeterImperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. (author)
  • Ganguly, SiddharthaUniv Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA. (author)
  • Hamadani, MehdiMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Inamoto, YoshihiroNatl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan. (author)
  • Jagasia, MadanVanderbilt Univ, Med Ctr, Nashville, TN USA. (author)
  • Kamble, RammurtiBaylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA. (author)
  • Koreth, JohnDana Farber Canc Inst, Dept Med Oncol, Ctr Hematol Oncol, Boston, MA 02115 USA. (author)
  • Lazarus, Hillard M.Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. (author)
  • Liesveld, JaneUniv Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. (author)
  • Litzow, Mark R.Mayo Clin, Div Hematol, Rochester, NY USA.;Mayo Clin, Transplant Ctr, Rochester, NY USA. (author)
  • Marks, David I.Univ Hosp Bristol Natl Hlth Serv Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England. (author)
  • Nishihori, TaigaH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. (author)
  • Olsson, Richard F.Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden.(Swepub:uu)riols677 (author)
  • Reshef, RanColumbia Univ, Med Ctr, Blood & Marrow Transplantat Program, New York, NY USA.;Columbia Univ, Med Ctr, Columbia Ctr Translat Immunol, New York, NY USA. (author)
  • Rowe, Jacob M.Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel. (author)
  • Saad, Ayman A.Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. (author)
  • Sabloff, MitchellUniv Ottawa, Dept Med, Div Hematol, Ottawa, ON, Canada.;Ottawa Hosp, Res Inst, Ottawa, ON, Canada. (author)
  • Schouten, Harry C.Acad Hosp Maastricht, Dept Hematol, Maastricht, Netherlands. (author)
  • Shea, Thomas C.Univ North Carolina Hlth Care, Dept Med, Div Hematol & Oncol, Chapel Hill, NC USA. (author)
  • Soiffer, Robert J.Dana Farber Canc Inst, Dept Med Oncol, Ctr Hematol Oncol, Boston, MA 02115 USA. (author)
  • Uy, Geoffrey L.Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. (author)
  • Waller, Edmond K.Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. (author)
  • Wiernik, Peter H.Our Lady Mercy Med Ctr, Bronx, NY USA. (author)
  • Wirk, BadeepSeattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA. (author)
  • Woolfrey, Ann E.Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. (author)
  • Bunjes, DonaldUlm Univ Hosp, Dept Internal Med 3, Ulm, Germany. (author)
  • Devine, StevenOhio State Univ, Dept Internal Med, Comprehens Canc Ctr James, Columbus, OH 43210 USA. (author)
  • de Lima, MarcosUniv Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA. (author)
  • Sandmaier, Brenda M.Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.;Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. (author)
  • Weisdorf, DanNatl Marrow Donor Program Be Match, Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. (author)
  • Khoury, Hanna JeanEmory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. (author)
  • Saber, WaelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Wayne State Univ, Karmanos Canc Inst, Dept Oncol, 4100 John R,4 HWCRC, Detroit, MI 48201 USA.Vanderbilt Univ, Med Ctr, Nashville, TN USA. (creator_code:org_t)

Related titles

  • In:Cancer: Wiley122:19, s. 3005-30140008-543X1097-0142

Internet link

Find in a library

  • Cancer (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view